Copernicus SOCT receives FDA clearance

Article

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

Reichert has received 510k clearance from the FDA to market the Reichert-Optopol Spectral Optical Coherence Tomographer (SOCT) in the US.

The Copernicus is designed for in vivo imaging and measurement of the retina by using spectral tomography to rapidly create high-resolution images of retinal structures. These detailed three-dimensional images enhance a physician's ability to diagnose and monitor retinal disease and perform pre- and post procedural assessments of patients.

The SOCT was the first commercially available device on the world market.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.